Section Arrow
PHVS.NASDAQ
- Pharvaris NV
Quotes are at least 15-min delayed:2026/01/05 07:20 EST
Pre Market
Last
 --
-- (--)
Bid
25.57
Ask
27.45
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 26.48
-1.27 (-4.58%)
Day High 
28.43 
Prev. Close
27.75 
1-M High
29.797 
Volume 
293.56K 
Bid
25.57
Ask
27.45
Day Low
26.18 
Open
27.96 
1-M Low
23.15 
Market Cap 
1.79B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 25.81 
20-SMA 25.57 
50-SMA 24.52 
52-W High 29.797 
52-W Low 11.51 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.90/-2.99
Enterprise Value
1.79B
Balance Sheet
Book Value Per Share
5.65
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
Pre Market 0.6991 +0.0391 +5.92%
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
Pre Market 0.5413 +0.0309 +6.05%
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
Pre Market 4.71 +0.36 +8.28%
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
Pre Market 0.1438 +0.0069 +5.04%
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Pre Market 4.28 +0.08 +1.90%
Industry overview quotes are at least 15 minutes delayed
Business Description
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel smallmolecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.